Microtech, a Medinol subsidiary, has successfully completed the first U.S. implantations of its atrial-pressure microsensor as part of a First-in-Human (FIH) study. This innovative device, implanted in patients undergoing LVAD (Left Ventricular Assist Device) procedures at NewYork-Presbyterian/Columbia University Irving Medical Center, represents a new class of microsensors. Notably passive and devoid of any electronics or antenna, the microsensor transmits data via ultrasound—enabling a highly miniaturized, energy-efficient, and biocompatible monitoring solution for continuous cardiac pressure assessment.

Designed to be both a standalone sensor and an integrated module on existing implants, the Microtech atrial-pressure microsensor has the potential to transform conventional therapeutic devices into intelligent diagnostic tools. Its minimal implantation time—only about five minutes with slight procedural modification—makes it a practical enhancement to standard LVAD surgery. The device's ability to non-invasively and accurately measure left and right atrial pressures over time offers clinicians valuable hemodynamic data, helping them tailor therapy based on precise physiological metrics rather than relying solely on symptomatic evaluation.

This milestone signals a major advancement in heart failure management and cardiac care. With a total of seven sensors now implanted between Israel and the U.S., the ongoing FIH study aims to enroll approximately 15 patients to further validate safety, feasibility, and efficacy. Microtech’s technology underscores a future where cardiac implants are not only life-supporting but also intelligent, diagnostic-enabled systems. This development could pave the way for smarter, more personalized treatment strategies and long-term improvements in patient outcomes.

MedTech Spectrum's Summary

Innovative Diagnostic Technology: Microtech’s atrial-pressure microsensor introduces a groundbreaking, passive, ultrasound-powered design that enables real-time, non-invasive cardiac pressure monitoring without electronics or antennas.

Enhanced Patient Care: The device allows clinicians to monitor left and right atrial pressures continuously, supporting precise, parameter-based treatment in patients with advanced heart failure and LVADs.

Paving the Way for Smart Implants: With successful implantations in the U.S. and Israel, the FIH study demonstrates the potential to integrate this microsensor into existing implants, unlocking a future of intelligent, multifunctional cardiac devices.